These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9768368)

  • 1. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents.
    Kadiri A; Chraibi A; Marouan F; Ababou MR; el Guermai N; Wadjinny A; Kerfati A; Douiri M; Bensouda JD; Belkhadir J; Arvanitis Y
    Diabetes Res Clin Pract; 1998 Jul; 41(1):15-23. PubMed ID: 9768368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe.
    Graff MR; McClanahan MA
    Clin Ther; 1998; 20(3):486-96. PubMed ID: 9663364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with NovoPen II and insulin Protaphane HM Penfill.
    Kølendorf K; Beck-Nielsen H; Oxenbøll B
    Postgrad Med J; 1988; 64 Suppl 3():14-6; discussion 21. PubMed ID: 3074294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen.
    Saurbrey N; Arnold-Larsen S; Møller-Jensen B; Kühl C
    Diabet Med; 1988 Mar; 5(2):150-3. PubMed ID: 2964981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient acceptance and issues of education of two durable insulin pen devices.
    Asakura T; Seino H; Jensen KH
    Diabetes Technol Ther; 2008 Aug; 10(4):299-304. PubMed ID: 18715204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of 25 years' experience with the NovoPen family of insulin pens in the management of diabetes mellitus.
    Hyllested-Winge J; Jensen KH; Rex J
    Clin Drug Investig; 2010; 30(10):643-74. PubMed ID: 20701399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, comparative crossover handling trial between two durable pens in patients with type 1 or 2 diabetes mellitus.
    Sommavilla B; Pietranera G
    J Diabetes Sci Technol; 2011 Sep; 5(5):1212-21. PubMed ID: 22027321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens.
    Brunton S
    Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of 20 years' experience with the NovoPen family of insulin injection devices.
    Rex J; Jensen KH; Lawton SA
    Clin Drug Investig; 2006; 26(7):367-401. PubMed ID: 17163272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of insulin loss in treatment of diabetics using the classical syringe or the insulin pen (Novopen II)].
    Krahulec B; Strbová L; Seböková E; Cárský J; Klimes I
    Vnitr Lek; 1996 Sep; 42(9):640-5. PubMed ID: 8984774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPen) in insulin-dependent diabetes mellitus.
    Small M; MacRury S; Boal A; Paterson KR; MacCuish AC
    Diabetes Res; 1988 Jun; 8(2):85-9. PubMed ID: 3067951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.
    Stockl K; Ory C; Vanderplas A; Nicklasson L; Lyness W; Cobden D; Chang E
    Curr Med Res Opin; 2007 Jan; 23(1):133-46. PubMed ID: 17257475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
    Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
    Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with NovoPen, an injection device using cartridged insulin, for diabetic patients.
    Walters DP; Smith PA; Marteau TM; Brimble A; Borthwick LJ
    Diabet Med; 1985 Nov; 2(6):496-7. PubMed ID: 2951126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus on Choice of Insulin Pen Devices in Routine Clinical Practice in India.
    Gupta A; Phatak S; Rao YS; Ramesh J; Sanyal D
    Diabetes Technol Ther; 2020 Oct; 22(10):777-786. PubMed ID: 32233934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nurse satisfaction using insulin pens in hospitalized patients.
    Davis EM; Bebee A; Crawford L; Destache C
    Diabetes Educ; 2009; 35(5):799-809. PubMed ID: 19633151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of unstable diabetes mellitus in children and adolescents using insulin administered by a semi-automated syringe, NovoPen].
    Necić S; Nikezić M; Sajić S; Radmanović S
    Srp Arh Celok Lek; 1989; 117(7-8):453-8. PubMed ID: 2688138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.